New member! AbolerIS Pharma, a Belgian biopharmaceutical company developing an entirely novel approach to the treatment of chronic autoimmune and inflammatory diseases, joined #BioWin health cluster. AbolerIS Pharma has recently secured an impressive โฌ27.3 million in a Series A funding, reinforcing its position as a key player in Wallonia's biotech sector and highlighting the region's attractiveness for foreign biotech investments. ๐ Learn more: https://lnkd.in/es_RYSfQ
BioWin - The Health Cluster of Walloniaโs Post
More Relevant Posts
-
Life Science partner providing staffing solutions for Business Development and Commercial Teams ๐งฌ๐ง๐ค๐ง
๐๐ฆ๐๐ซ๐ ๐ข๐ง๐ ๐๐ข๐จ๐ญ๐๐๐ก ๐ Upstream Bio ๐๐๐๐๐๐ $200๐ด ๐๐ ๐บ๐๐๐๐๐ ๐ฉ ๐ญ๐๐๐๐๐๐๐๐๐ต ๐๐ ๐จ๐ ๐๐๐๐๐ ๐จ๐๐๐๐๐ ๐ซ๐๐๐. Upstream Bio, a clinical-stage biopharmaceutical company developing novel medicines for respiratory diseases, recently announced the funding. The round was led by Enavate Sciences and VENROCK HEALTHCARE CAPITAL PARTNERS LP, with participation from new investors Bain Capital Life Sciences Fund LP and Wellington Management. The proceeds from the financing will be used to advance Upstream Bio's lead product candidate, UPB-101, into Phase 2 trials for asthma and chronic rhinosinusitis with nasal polyps. ๐ฌ"๐๐ฆ ๐ฃ๐ฆ๐ญ๐ช๐ฆ๐ท๐ฆ ๐ต๐ฉ๐ข๐ต ๐๐๐-101 ๐ฉ๐ข๐ด ๐ต๐ฉ๐ฆ ๐ฑ๐ฐ๐ต๐ฆ๐ฏ๐ต๐ช๐ข๐ญ ๐ต๐ฐ ๐ฃ๐ฆ ๐ข ๐ต๐ณ๐ข๐ฏ๐ด๐ง๐ฐ๐ณ๐ฎ๐ข๐ต๐ช๐ท๐ฆ ๐ต๐ณ๐ฆ๐ข๐ต๐ฎ๐ฆ๐ฏ๐ต ๐ง๐ฐ๐ณ ๐ข๐ด๐ต๐ฉ๐ฎ๐ข ๐ข๐ฏ๐ฅ ๐ค๐ฉ๐ณ๐ฐ๐ฏ๐ช๐ค ๐ณ๐ฉ๐ช๐ฏ๐ฐ๐ด๐ช๐ฏ๐ถ๐ด๐ช๐ต๐ช๐ด ๐ธ๐ช๐ต๐ฉ ๐ฏ๐ข๐ด๐ข๐ญ ๐ฑ๐ฐ๐ญ๐บ๐ฑ๐ด, ๐ข๐ฏ๐ฅ ๐ธ๐ฆ ๐ข๐ณ๐ฆ ๐จ๐ณ๐ข๐ต๐ฆ๐ง๐ถ๐ญ ๐ง๐ฐ๐ณ ๐ต๐ฉ๐ฆ ๐ด๐ถ๐ฑ๐ฑ๐ฐ๐ณ๐ต ๐ฐ๐ง ๐ฐ๐ถ๐ณ ๐ฏ๐ฆ๐ธ ๐ข๐ฏ๐ฅ ๐ฆ๐น๐ช๐ด๐ต๐ช๐ฏ๐จ ๐ช๐ฏ๐ท๐ฆ๐ด๐ต๐ฐ๐ณ๐ด." - ๐๐ซ. ๐๐๐ซ๐ค ๐๐๐๐ค๐๐ซ, ๐๐๐ ๐จ๐ ๐๐ฉ๐ฌ๐ญ๐ซ๐๐๐ฆ ๐๐ข๐จ. Asthma is a chronic condition that affects millions of people worldwide, Upstream Bio's therapy has the potential to be a more effective and safer treatment than current therapies.๐ ๐๐ก๐ ๐๐ก๐๐ฌ๐ 2 ๐ญ๐ซ๐ข๐๐ฅ๐ฌ ๐๐จ๐ซ ๐๐๐-101 ๐๐ซ๐ ๐๐ฑ๐ฉ๐๐๐ญ๐๐ ๐ญ๐จ ๐๐๐ ๐ข๐ง ๐ข๐ง ๐ญ๐ก๐ ๐ฌ๐๐๐จ๐ง๐ ๐ก๐๐ฅ๐ ๐จ๐ 2023, ๐๐๐๐ข๐ง๐ข๐ญ๐๐ฅ๐ฒ ๐จ๐ง๐ ๐ญ๐จ ๐ค๐๐๐ฉ ๐ ๐๐ฅ๐จ๐ฌ๐ ๐๐ฒ๐ ๐จ๐ง.๐ #healthcare #people #lifesciences #ceo #funding #therapies #clinicaltrials #biotechnology #biopharmaceutical #asthma
-
-
As per DelveInsight, the Generalized Myasthenia Gravis Market size was USD 2,690 Million in 2021, which is anticipated to grow by 2032. Major pharma and biotech giants such as Alexion Pharmaceuticals, Inc., argenx, UCB, argenx, Horizon, Roche, Janssen Inc., Immunovant, among others, are actively working to explore novel therapeutics options in the Generalized Myasthenia Gravis Market. Learn how the Generalized Myasthenia Gravis (gMG) Market will evolve by 2032: https://lnkd.in/d5R9shxZ #lifesciences #marketresearch #marketanalysis #healthcare #markettrends #health #medical #generalizedmyastheniagravisย #myastheniagravis
-
Senior Manager, Marketing at Waters Corp โข Biopharma & Bioprocessing โข Inspiring and creative leader driving customer success and business growth โข LC & MS expert
**Celebrating 5 years of BioAccord LCMS: The evolution of a game-changer** Already five years ago, I was touring Benelux, Germany and Switzerland with Perry Derwig, Michael Dรฉsor and Jan Claereboudt as we were launching the BioAccord LCMS system. What a series of events it was, at the heart of local biopharma communities and hotspots! Looking back, we can say we were about to change the game in biopharma analysis, with a revolutionary solution for routine monitoring in biopharmaceutical process and product development. Since then, hundreds of users around the world have experienced the benefits of this system, which has evolved to meet the changing needs of the industry. Whether it's protein therapeutics, bioprocess, peptide MAM, or nucleic acid analysis, the BioAccord LCMS system delivers. We are proud of how far we have come, and we are excited for what the future holds. Join us as we celebrate this milestone and learn more about the BioAccord LCMS system here: www.waters.com/bioaccord Waters Corporation #biopharma
-
